{
    "clinical_study": {
        "@rank": "114422", 
        "arm_group": [
            {
                "arm_group_label": "Test 1 (Treatment A)", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose of dabigatran"
            }, 
            {
                "arm_group_label": "Test 2 (Treatment B)", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose of dabigatran"
            }, 
            {
                "arm_group_label": "Reference", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose of dabigatran"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the relative bioavailability of dabigatran etexilate as pellets on food and\n      of dabigatran etexilate as granules resolved in reconstitution solution, each with\n      dabigatran etexilate as capsule following oral administration. To evaluate acceptability and\n      palatability of Pellets sprinkled on food and Oral Liquid Formulation"
        }, 
        "brief_title": "Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males according to the investigator's assessment, as based on the following\n             criteria: a complete medical history including a physical examination, vital signs\n             (Blood Pressure, Pulse Rate), 12-lead electrocardiogram, and clinical laboratory\n             tests\n\n          2. Age 18 to 55 years (incl.)\n\n          3. Body Mass Index 18.5 to 29.9 kg/m2 (incl.)\n\n          4. Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including Blood Pressure, Pulse Rate or\n             electrocardiogram) deviating from normal and judged clinically relevant by the\n             investigator.\n\n          2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic\n             blood pressure greater than 90 mm Hg\n\n          3. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          4. Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the study\n             drug\n\n          7. Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders\n\n          8. Subjects who in the investigator's judgement are perceived as having an increased\n             risk of bleeding, for example because of:\n\n               -  Hemorrhagic disorders or bleeding diathesis\n\n               -  Occult blood in faeces or haematuria\n\n               -  Trauma or surgery within the last month or as long as an excessive risk of\n                  bleeding persists after these events, or planned surgery during trial\n                  participation\n\n               -  History of arteriovenous malformation or aneurysm\n\n               -  History of gastroduodenal ulcer disease or gastrointestinal haemorrhage\n\n               -  History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic\n                  intraarticular bleeding\n\n               -  Anemia at screening\n\n               -  Thrombocytopenia (platelet count less than 100/nL)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044367", 
            "org_study_id": "1160.194", 
            "secondary_id": "2013-002498-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test 1 (Treatment A)", 
                "description": "Pellets (multiple dose of dabigatran)", 
                "intervention_name": "Dabigatran etexilate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test 2 (Treatment B)", 
                "description": "Granules resolved in reconstitution solution (multiple dose of dabigatran)", 
                "intervention_name": "Dabigatran etexilate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference", 
                "description": "Hard capsule (multiple dose of dabigatran)", 
                "intervention_name": "Dabigatran etexilate", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1160.194.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, Randomised, Multiple-dose, Three Way Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for total dabigatran.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044367"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acceptability rating for pellets (on food) and oral solution will be assessed by asking the subjects 2 multiple choice verbal questions.", 
                "safety_issue": "No", 
                "time_frame": "once on day 3 (48 hours after first dose)"
            }, 
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t for free dabigatran.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Palatability rating for pellets (on food) and oral solution will be assessed by asking the subjects 2 multiple choice verbal questions.", 
                "safety_issue": "No", 
                "time_frame": "once on day 3 (48 hours after first dose)"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}